Ascend Wellness (AAWH) Q4 2024 earnings summary

Executive summary

• Achieved significant profitability and cash flow improvements, with adjusted EBITDA margin up 450 bps to $30.2M, a 20.4% sequential increase in Q4 2024.

• Completed $30M in annualized cost savings, driving margin expansion and operational efficiency.

• Eighth consecutive quarter of positive cash from operations, with Q4 free cash flow at $30.1M and cash balance rising to $88.3M.

• Initiated a share buyback, repurchasing 11M shares (over 5% of outstanding) and launching a new buyback program.

• Launched Effin', now the top-selling edible brand in stores, and refreshed nearly 350 SKUs to enhance product offering.

Financial highlights

• FY 2024 net revenue reached $562M, up 8.3% year-over-year, driven by wholesale expansion and new dispensaries.

• Adjusted EBITDA increased 9.1% to $116.2M; Q4 adjusted EBITDA was $30.2M, up 20.4% quarter-over-quarter.

• Q4 2024 net revenue was $136M, down 4% sequentially; retail and wholesale revenues fell 3.5% and 5.0%, respectively.

• FY 2024 gross profit was $184.2M (32.8% margin); Adjusted Gross Profit was $225.9M (40.2% margin).

• Cash and equivalents at year-end were $88.3M; net working capital improved to $84.8M.

Outlook and guidance

• Expect mid-single-digit % revenue decline in Q1 2025 due to softer consumer spending and weather impacts.

• Adjusted EBITDA margin anticipated to remain above 20% in Q1, with margin and top-line gains expected in H2 2025.

• Densification strategy aims for 50% store base growth, with several new dispensaries expected in H2 2025.

• CapEx for 2025 projected at $30–$35M, about half allocated to new store openings.

• Management expects to implement further cost savings and efficiency measures in 2025.